ACE Technology Guidances

ACE Technology Guidances communicate recommendations from the MOH Drug Advisory Committee or the MOH Medical Technology Advisory Committee on the funding status and appropriate use of drugs, vaccines or medical technologies that have been evaluated by ACE. The guidances also include the Committee’s rationale for the funding recommendations, and key clinical and economic evidence which informed their deliberations. Plain English Summaries (PES) to explain ACE Technology Guidances are available for patients and the public.

Published on 13 Sep 2024
Last Updated on 13 Sep 2024

A- A+

Guidance Recommendations
The Ministry of Health’s Drug Advisory Committee has not recommended selexipag for inclusion on the MOH List of Subsidised Drugs as an add-on therapy for patients with pulmonary arterial hypertension who are insufficiently controlled with an endothelin receptor antagonist and/or a phosphodiesterase type 5 inhibitor. The decision was based on the unfavourable cost effectiveness of selexipag compared with placebo at the prices proposed by the company.

Guidance Recommendations

The Ministry of Health’s Drug Advisory Committee has not recommended selexipag for inclusion on the MOH List of Subsidised Drugs as an add-on therapy for patients with pulmonary arterial hypertension who are insufficiently controlled with an endothelin receptor antagonist and/or a phosphodiesterase type 5 inhibitor. The decision was based on the unfavourable cost effectiveness of selexipag compared with placebo at the prices proposed by the company.

Selexipag for treating pulmonary arterial hypertension (Published 13 Sep 2024) PES Selexipag for treating pulmonary arterial hypertension (Published 13 Sep 2024)